86
Participants
Start Date
August 18, 2022
Primary Completion Date
February 7, 2025
Study Completion Date
February 7, 2025
Pegylated Liposomal Doxorubicin + SL-172154
The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Mirvetuximab + SL-172154
The investigational product, SL-172154, is a novel fusion protein consisting of human SIRPα and CD40L (SIRPα -Fc-CD40L) linked via a human Fc.
Hospital Universitario Dr. Josep Trueta - ICO de Girona, Servicio de Oncología Av. Francia s/n, Girona
Hospital Universitari Vall D Hebron, Madrid
Hospital Universitario Fundacion Jimenez Diaz START Madrid-FJD- Unidad de Ensayos Fase I, Madrid
Hospital Universitario Virgen de la Arrixaca. Servicio de Oncología Ctra. Madrid-Cartagena, s/n, Murcia
START Midwest, Grand Rapids
Robert H.Lurie ComprehensiveCancer Center, Northwestern University, Chicago
University of Arkansas for Medical sciences, Little Rock
Stephenson Cancer Center, OU Health/ Sarah Cannon Research Institute, Oklahoma City
City of Hope, Duarte
BC Cancer Center, Vancouver
University health Network (UHN)-University of Toronto, Toronto
McGill University Health Care, Montreal
Hospital Universitari Germans Trias i Pujol, Badalona
Hospital Universitario Quirón-Dexeus Servicio de Oncologia Médica, Barcelona
Hospital Clinic de Barcelona Servicio de Oncología, Esc. 2, Planta 5 dcha, Barcelona
Lancashire Teaching Hospitals NHS Foundation Trust, Preston
Guy's & St Thomas' NHS Foundation Trust, London
The Royal Marsden NHS Foundation Trust, London
University College London Hospitals NHS Foundation Trust, London
The Christie NHS Foundation Trust, Manchester
The Royal Marsden NHS Foundation Trust, Sutton
Shattuck Labs, Inc.
INDUSTRY